Enobosarm Has Antitumor Activity in ER-Positive, HER2-Negative Advanced Breast Cancer
TUESDAY, Feb. 27, 2024 -- The oral selective androgen receptor modulator enobosarm has antitumor activity and can yield clinical benefit in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2024 Category: Pharmaceuticals Source Type: news
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), (Source: World Pharma News)
Source: World Pharma News - February 27, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
New $5 breast cancer spit test can spot disease in five SECONDS by analyzing saliva for danger proteins
Researchers in Florida and Taiwan developed a handheld device that costs roughly $5 total and can detect breast cancer markers like the HER2 protein in as little as five seconds. (Source: the Mail online | Health)
Source: the Mail online | Health - February 13, 2024 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
Expert discussion on key data for CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer including guidance on clinical implementation of shared-decision making with patients.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Breast imaging features tied to pathological findings in young women
Imaging features are tied to pathological findings in breast cancer among young women, a study published January 26 in Clinical Imaging found.
Researchers led by Sepideh Sefidbakht, MD, from the Mohammad Rasool Allah Research Tower in Shiraz, Iran found that round and oval masses on mammography are more common in triple-negative and Luminal B cancers. Additionally, hypoechoic mass and posterior shadowing are the most common findings in breast ultrasound upon diagnosis.
“Given the rising incidence and geographical/ethnic variability of breast cancer in young women, physician awareness is crucial for timely diagnoses an...
Source: AuntMinnie.com Headlines - January 29, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Source Type: news
MRI radiomics shows potential in determining breast cancer HER2 status
MRI radiomics features can differentiate breast cancers based on human epidermal growth factor receptors (HERs), according to research published January 24 in the American Journal of Roentgenology.
Researchers led by Yuqin Peng from Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University in Guangzhou, Guangdong found that their nomogram based on MRI radiomics can distinguish HER2-zero from HER2-low or HER2-positives cancers, as well as HER2-low from HER2-positive cancers.
“MRI radiomics may help select patients for novel or traditional HER2-targeted therapies, particularly in those with ambiguous immunohistochemical resu...
Source: AuntMinnie.com Headlines - January 25, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties MRI Breast Imaging Source Type: news
MDT model in breast cancer MDT model in breast cancer
Value of multidisciplinary care in early HR+/ HER2- breast cancerMedscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
Multiparametric MRI helps predict breast cancer treatment outcomes
Multiparametric MRI helps predict breast cancer treatment response, according to a report on the RSNA's Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge published January 5 in Radiology: Imaging Cancer.
The findings suggest that MRI could offer an effective way to tailor the care of women with the disease, wrote a team led by Wen Li, PhD, of the University of California, San Francisco.
"Outcomes of the BMMR2 challenge provide further compelling evidence of the value of functional breast MRI as an early marker of treatment response that may aid in critical escalation and de-...
Source: AuntMinnie.com Headlines - January 8, 2024 Category: Radiology Authors: Kate Madden Yee Tags: MRI Womens Imaging Breast Imaging Source Type: news
Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer
(MedPage Today) -- A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 4, 2024 Category: Hematology Source Type: news
Understanding triple-negative breast cancer and its treatment
There are several breast cancer subtypes. The growth of hormone-dependent breast cancer, the most common subtype, is driven by female hormones. Another common subtype, HER2-positive breast cancer, has excessive copies of a gene called HER2 that makes its cells grow more than they should. Triple-negative breast cancer, also called basal-like breast cancer, is a subtype that isn't affected by hormones or the HER2 gene. It grows rapidly, is more likely to spread beyond the breast… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 4, 2024 Category: Databases & Libraries Source Type: news
Key Abstracts in HER2-Positive Breast Cancer From SABCS 2023 Key Abstracts in HER2-Positive Breast Cancer From SABCS 2023
Highlights in HER2+ breast cancer from SABCS 2023 include data from the HER2CLIMB-02 trial of tucatinib plus T-DM1 and a 9-year follow-up of the KATHERINE trial, as discussed by Dr Harold Burstein.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2024 Category: Consumer Health News Tags: None ReCAP Source Type: news
